ReviewBreast cancer research : BCR2012
Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?
Review in Breast cancer research : BCR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer.Breast cancer research and treatment · 2021Trial
- Nitrogen-Based Bisphosphonate Use and Risk of Cancer in Women Aged 50 Years and Older: A National Data Linkage Study.International journal of cancer · 2026Article
- Anti‑metastatic activity of aromatic aminomethylidenebisphosphonates in a mouse model of 4T1 cell‑derived breast cancer.Oncology reports · 2023Article
- ICAM1 promotes bone metastasis via integrin-mediated TGF-β/EMT signaling in triple-negative breast cancer.Cancer science · 2022Article
- Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor-treated patients with non-small cell lung cancer exhibiting bone metastasis.Oncology letters · 2019Article
- Bone Metastasis Prognostic Factors in Breast Cancer.Breast cancer : basic and clinical research · 2019Article
- Bone metastasis pattern in initial metastatic breast cancer: a population-based study.Cancer management and research · 2018Article
- Effect of a local, one time, low-dose injection of zoledronic acid on titanium implant osseointegration in ovariectomized rats.Archives of medical science : AMS · 2016Article
- Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.Clinical & experimental metastasis · 2016Article
- Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Targeting tumor-stromal interactions in bone metastasis.Pharmacology & therapeutics · 2014Review
- Article
- The Roles of Epithelial-to-Mesenchymal Transition (EMT) and Mesenchymal-to-Epithelial Transition (MET) in Breast Cancer Bone Metastasis: Potential Targets for Prevention and Treatment.Journal of clinical medicine · 2013Review
- Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?Journal of clinical medicine · 2013Review
- Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate!Journal of thoracic disease · 2013Article
- SLFN12 Over-expression Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy Drugs and Radiotherapy.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zoledronic acid (ZA) is an imidazole-containing bisphosphonate that has been extensively studied as an osteoclast inhibitor. ZA decreases bone turnover and has been effective in limiting osteolysis in metastatic cancers, including breast cancer. Recent clinical trials that demonstrated enhancement of disease-free survival by bisphosphonates have prompted interest in bisphosphonates as anti-cancer agents. ZA, for example, increased disease-free survival in postmenopausal and in premenopausal, hormone-suppressed breast cancer patients. Intriguingly, however, there was a lack of an anti-cancer effect of ZA in premenopausal women without ovarian suppression. These observations have prompted the conjecture that anti-cancer effects of ZA are limited to estrogen-poor environments. This review explores possible mechanisms compatible with differences in ZA activity in premenopausal women compared with postmenopausal (or hormone-suppressed) women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.